
Licensed to fill prescriptions for patients in RI, MA, CT, NJ, NH, FL, ME and PA. New York patients are served on a limited basis while nonresident registration is pending.
Prepared to a prescriber's order for one patient. Not FDA-approved.
This is a compounded oral solution containing magnesium sulfate heptahydrate, prepared to a prescriber's order for one patient. Compounded preparations are not FDA-approved.
These listings cover every salt or ester form of each drug in the FDA National Drug Code Directory.
FDA-approved products containing magnesium sulfate alone are listed in injection form. Other FDA-approved products contain it only in combination with other active ingredients, in oral solution, tablet and irrigant forms, and it is a component of an FDA-approved bowel preparation kit. No FDA-approved product contains magnesium sulfate alone for use by mouth. Single-ingredient oral products are filed as over-the-counter monograph granules and crystals.
Liquid bases can be aqueous or nonaqueous, and USP <795> classifies the preparation by its water activity. Aqueous preparations carry shorter default beyond-use dates than nonaqueous ones. The date printed on the label is the one to follow.
Compounded drugs are not FDA-approved. This means that FDA does not review these drugs to evaluate their safety, effectiveness, or quality before they reach patients.
Magnesium sulfate heptahydrate is a magnesium salt (electrolyte and saline laxative), given by injection or by mouth, that a pharmacy may compound on prescription.
Magnesium sulfate heptahydrate (MgSO4 with seven water molecules) is the crystalline form of magnesium sulfate, a salt that supplies magnesium. Magnesium is a cofactor for many enzyme reactions and helps control nerve signaling and muscle excitability. Prescription magnesium sulfate injection, made from the heptahydrate (for example, Fresenius Kabi, NDA), is labeled for replacing magnesium in deficiency, especially acute low magnesium with tetany, for adding to total parenteral nutrition, and for preventing and controlling seizures in pre-eclampsia and eclampsia. Over the counter, magnesium sulfate heptahydrate is sold as Epsom salt, filed on DailyMed as an OTC monograph drug and labeled as a saline laxative for occasional constipation. A prescriber might order magnesium sulfate compounded in a strength or form that is not manufactured, or without a particular excipient. Compounded preparations are not FDA-approved and require a prescription.
The injection label has no boxed warning but warns that continuous use for more than 5 to 7 days during pregnancy can cause low calcium and weakened bones in the developing baby, and fractures have been reported in newborns. Do not receive the injection if you have heart block or heart muscle damage. Kidney problems raise the risk of too much magnesium, which can cause flushing, sweating, low blood pressure, weak reflexes, slowed breathing and heart problems. It can add to sedatives, opioids and anesthetics, strengthen surgical muscle-blocking drugs, and needs extra caution with digoxin. The Epsom salt label says to ask a doctor before using it as a laxative if you have kidney disease or are on a magnesium-restricted diet, and to separate it from other drugs by 2 or more hours. LactMed says maternal use is not expected to affect a breastfed infant's magnesium. Talk to your prescriber or pharmacist about side effects.
Magnesium is a cofactor in enzymatic reactions; per the Fresenius Kabi label it prevents or controls convulsions by blocking neuromuscular transmission and decreasing acetylcholine release at the motor end-plate, and produces peripheral vasodilation. StatPearls adds that Mg2+ competes at voltage-gated calcium channels. Per the label, IV onset of anticonvulsant action is immediate and lasts about 30 minutes, IM onset is about one hour and persists three to four hours, and magnesium is excreted solely by the kidneys in proportion to plasma concentration and glomerular filtration. Labeled indications (injection, NDA): magnesium deficiency, TPN additive, and seizure prevention and control in pre-eclampsia and eclampsia. StatPearls lists acute asthma exacerbations, torsades de pointes and tocolysis as non-FDA-approved uses; the label notes efficacy and safety for preterm labor are not established. Monitor serum magnesium, patellar reflexes, respiratory rate and urine output per the label, and confirm hypomagnesemia before use. Use with caution in renal impairment. The injection contains aluminum. An injectable calcium salt should be available for toxicity. Dosing is per prescriber.
Measure each dose with the oral syringe or dosing cup provided, using the milliliter markings. Do not use household spoons. Take it by mouth as your label directs, with or without food as instructed. Rinse the measuring device after use and keep the bottle capped.
Oral solutions are aqueous. Under USP <795>, a preserved solution usually carries a beyond-use date of up to 35 days at room temperature or refrigerated, and an unpreserved one 14 days refrigerated. Your label shows whether to refrigerate and the beyond-use date. Keep out of reach of children and discard after that date.
This formulation is compounded by Bayview Pharmacy on a prescriber's order for an individual patient. It is not an FDA-approved drug product, and the FDA has not evaluated it for safety, effectiveness, or manufacturing quality.
A valid prescription is required. Availability depends on Bayview's licensure in your state. This page is general information, not medical advice. Discuss your situation with a licensed healthcare provider.
Search by NCPDP 4106882, or by name and ZIP: Bayview Pharmacy, Warwick, RI 02886. Select it as the destination pharmacy and save it as a favorite. Click any value to copy it.
Compounded preparations have no NDC, so this formula will not appear in your EHR's drug search. Use your system's compound, non-formulary, or free-text prescription entry and name the preparation exactly as written in step 3. If your EHR forces you to pick a listed drug, pick the closest entry for the active ingredient and put the full formula in the prescription body (the Sig or directions field), not in Notes to Pharmacy.
Compounded preparations have no NDC and will not appear in your drug search. For EPCS to validate, select a drug entry your EHR recognizes as controlled, usually the bulk powder entry for the active ingredient (for example Ketamine (bulk) powder, not a branded product), then put the full formula from step 3 in the prescription body. A free-text entry that does not validate as controlled will be rejected by your EPCS module.
Quantity and directions are starting points for this dose form, not treatment recommendations. Dosing remains the prescriber's responsibility.
Transmit from your EHR. For this non-controlled preparation we also accept fax to (401) 284-4506 and phoned orders at (401) 284-4505. Order forms are on the formulation pages and in the prescriber portal.
Transmit with two-factor authentication through your EPCS-enabled EHR. No order form is offered for this preparation; e-prescribing guides for our controlled preparations are on the formulation pages.
Licensed to dispense in RI, MA, CT, NJ, NH, FL, ME, and PA; New York is served on a limited basis while nonresident registration is pending. Compounded preparations are not FDA-approved. A valid prescription is required. Full guide, including steps by EHR: How to e-prescribe to Bayview. Questions about this formula: call (401) 284-4505.
Take orally